Twist Bioscience Corporation

Equities

TWST

US90184D1000

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-10 pm EDT 5-day change 1st Jan Change
50.99 USD +0.97% Intraday chart for Twist Bioscience Corporation +6.23% +38.33%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating MT
Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A MT
Twist Bioscience Corporation Launches Synthetic RNA Control for H5N1 Influenza A CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 3000E Value Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 3000 Value Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 2500 Value Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell Small Cap Comp Value Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 3000 Growth Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 2000 Value Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 3000E Growth Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 2000 Growth Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 2500 Growth Index CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell Small Cap Comp Growth Index CI
Barclays Adjusts Price Target on Twist Bioscience to $60 From $45, Maintains Overweight Rating MT
Transcript : Twist Bioscience Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor CI
Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target MT
Oxford Nanopore Technologies Collaborates with Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine CI
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-Throughput Screening Applications CI
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Twist Bioscience Shares Jump After Fiscal Q2 Beat, Fiscal 2024 Revenue Guidance Raised MT
Transcript : Twist Bioscience Corporation, Q2 2024 Earnings Call, May 02, 2024
Earnings Flash (TWST) TWIST BIOSCIENCE CORPORATION Posts Q2 Revenue $75.3M, vs. Street Est of $70.8M MT
Twist Bioscience Corporation Revises Earnings Guidance for the Fiscal Year 2024 CI
Chart Twist Bioscience Corporation
More charts
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
50.5 USD
Average target price
48.33 USD
Spread / Average Target
-4.29%
Consensus
  1. Stock Market
  2. Equities
  3. TWST Stock
  4. News Twist Bioscience Corporation
  5. Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A